| This week's sponsor is FierceBiotech Drug Development Forum. | |  | FierceBiotech 2nd Drug Development Forum - September 25-27 in Boston
90+ executive-level speakers share advanced partnership and pipeline strategies. Learn to adapt to increased deal complexity, real world evidence and digital technologies. Unequaled networking! Sign up by August 11 to save $200 on registration. |
Featured Story | | | Monday, July 17, 2017 The FDA has rejected Amgen’s application for approval of osteoporosis candidate romosozumab. Officials knocked back the filing after phase 3 data linked the sclerostin-targeting antibody to an increased risk of cardiovascular adverse events. |
|
|
Top Stories Monday, July 17, 2017 Philadelphia biotech Enterin has raised $12.7 million in funding to pursue its hypothesis that Parkinson's disease originates in the gut, not the brain. Monday, July 17, 2017 Small cap CymaBay Therapeutics has taken a look at its ongoing midstage test for its liver med seladelpar, and says it’s happy with what it sees. Monday, July 17, 2017 The United Kingdom has put together an £86 million ($112 million) package of funding to cut the time it takes for drugs and other medical advances to reach patients. Officials are making the cash available to start implementing Accelerated Access Review recommendations the U.K. sees establishing it as the first port of call for drug development in Europe. Monday, July 17, 2017 Diagnostics maker Quidel has penned a deal to acquire Alere’s triage assets as it boosts its position in the point of care market, as well as its geographic footprint. Monday, July 17, 2017 Scientists at the University of Pennsylvania have discovered three genetic variants that may enhance the immune system’s ability to fight Alzheimer’s—and that may be targetable with drugs. The variants are found in microglia, brain cells that surround amyloid plaques found in the brains of patients. Monday, July 17, 2017 With Amgen’s competing bone drug newly sidelined, Radius has a big opportunity ahead with its Tymlos launch, and now it has a new CEO to lead the way. Jesper Høiland, former president of Novo Nordisk’s U.S. business, has signed on to challenge Eli Lilly's Forteo—and its forthcoming generics—in the osteoporosis market. Monday, July 17, 2017 Check out today's best of the rest of biopharma news. Resources Sponsored By: Veeva Learn why 99% of respondents report the need to unify their clinical applications, including CTMS, EDC, eTMF, and study start-up. Sponsored By: DocuSign When leading biopharma companies founded SAFE-BioPharma in 2005, it was with a vision of a not too distant future with major changes in the industry: the move to collaboration with many partners, make business processes fully electronic, and to take advantage of all of the benefits of online operations. Sponsored By: Veeva Learn why 99% of respondents report the need to unify their clinical applications, including CTMS, EDC, eTMF, and study start-up. Sponsored By: HealthCore Gain critical insights into how to design and implement pragmatic trials and generate relevant, high-level real-world evidence. Learn when to conduct PTs, design considerations, ethical regulatory issues — and more. Sponsored By: Envigo Discover the factors that contribute to differential radiation sensitivity between the Rag2 and SCID models. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Sponsored By: Veeva Join this global webinar to learn a new approach for demonstrating medical affairs' impact with better metrics - beyond reach and frequency, enabling launch success and better engagement with strategic KOL insights, and increasing your organization's share of voice in the healthcare landscape. Sponsored By: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Sponsored By: DocuSign The patients who rely on your scientific leadership are expecting more. Sponsored By: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. |
|
